Team

Alex Barkas, In Memoriam

About

What We've Achieved

Prospect Venture Partners

Team

Alex Barkas, In Memoriam

About

What We've Achieved

David Schnell

November 9, 2018

November 9, 2018 - NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in NASH Patients

David Schnell

November 9, 2018

Source:https://www.ngmbio.com/ngm-bio-announces-new-histology-data-from-phase-2-trial-of-ngm282-in-patients-with-nash/

Newer PostNovember 12, 2018 - NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)

Older PostNovember 6, 2018 - NGM Bio Presents New NASH Histology Data (Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313)

Contact Prospect
Venture Partners:

Address:
525 University Ave., Suite 1350
Palo Alto, CA 94301

Phone:
(650) 327-8800

Prospect Ventures Funds:
Prospect Venture Partners I
Prospect Venture Partners II
Prospect Venture Partners III

Connect with Prospect Ventures:
Prospect Ventures on LinkedIn
Prospect Ventures on Crunchbase
Prospect Ventures on Bloomberg
Prospect Ventures on CB Insights
Prospect Ventures on Palico
Prospect Ventures on Index.co
Prospect Bio Ventures

© 2018 - Prospect Venture Partners.. All Rights Reserved
No content on this site may be republished or reprinted without written permission from Prospect Venture Partners